转录因子
生物
染色质
细胞生物学
抄写(语言学)
癌症研究
T细胞
免疫疗法
祖细胞
癌症免疫疗法
细胞
分子生物学
细胞毒性T细胞
CD28
基因
计算生物学
癌细胞
遗传学
细胞培养
祖细胞
DNA
转录组
作者
Rosa Maria Rubio,Gerardo Suárez‐Rojas,Adrián Albarrán‐Godínez,Saraí G De León-Rodríguez,Cristina Aguilar-Flores,Marco Antonio Fonseca-Montaño,Michelle Téllez-Sütterlin,Sofia Victoria de los Santos Carmona,Karla Guzmán-Barrenechea,Fernando Candanedo-González,Enrique Soto‐Pérez‐de‐Celis,Laura Gómez-Romero,Diego Cortez,Marysol González‐Yáñez,Laura C. Bonifaz,Iris Karina Madera-Salcedo,José Carlos Crispín,Florencia Rosetti
出处
期刊:Cell Reports
[Cell Press]
日期:2025-12-01
卷期号:44 (12): 116680-116680
被引量:6
标识
DOI:10.1016/j.celrep.2025.116680
摘要
Immunotherapy has revolutionized cancer treatment, but it lacks efficacy in a sizable fraction of patients. Therefore, understanding the transcriptional networks that limit CD8 + T cell anti-tumor responses is fundamental. Here, we show that the transcription factor Helios is induced in tumor-infiltrating CD8 + T cells in human and murine cancer. Genetic deletion of Helios in CD8 + T cells reduces tumor growth, decreases the number of intratumoral terminally exhausted CD8 + T cells, and increases the frequency of cells with a transcriptional profile indicative of progenitor capacity. These changes are associated with increased chromatin accessibility in loci encoding stemness-related genes. The combination of Helios and PD-1 deficiencies robustly improves the anti-tumoral capacity of CD8 + T cells. A Helios inhibitor, identified in a small-molecule screen, improves the anti-tumoral effects of PD-1 deficiency. These results demonstrate that Helios represents a therapeutic target that can boost anti-cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI